Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

244 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.
Garcia Garcia Y, de Juan Ferré A, Mendiola C, Barretina-Ginesta MP, Gaba Garcia L, Santaballa Bertrán A, Bover Barcelo I, Gil-Martin M, Manzano A, Rubio Pérez MJ, Romeo Marin M, Arqueros Núñez C, García-Martínez E, Gonzalez Martin A. Garcia Garcia Y, et al. Among authors: manzano a. Int J Gynecol Cancer. 2019 Jul;29(6):1050-1056. doi: 10.1136/ijgc-2019-000256. Int J Gynecol Cancer. 2019. PMID: 31263024 Clinical Trial.
Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study).
Tavira B, Iscar T, Manso L, Santaballa A, Gil-Martin M, García García Y, Romeo M, Iglesias M, de Juan Ferré A, Barretina-Ginesta MP, Manzano A, Gaba L, Rubio MJ, de Andrea CE, González-Martín A. Tavira B, et al. Among authors: manzano a. Clin Cancer Res. 2024 Jan 5;30(1):176-186. doi: 10.1158/1078-0432.CCR-23-0771. Clin Cancer Res. 2024. PMID: 37527007 Free PMC article.
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, González-Martín A, Jung KH, Ługowska I, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Fielding A, Ma Y, Puvvada S, Shire N, Lee JY. Meric-Bernstam F, et al. Among authors: manzano a. J Clin Oncol. 2024 Jan 1;42(1):47-58. doi: 10.1200/JCO.23.02005. Epub 2023 Oct 23. J Clin Oncol. 2024. PMID: 37870536 Free PMC article. Clinical Trial.
Targeted Agents in Cervical Cancer: Beyond Bevacizumab.
Marquina G, Manzano A, Casado A. Marquina G, et al. Among authors: manzano a. Curr Oncol Rep. 2018 Apr 2;20(5):40. doi: 10.1007/s11912-018-0680-3. Curr Oncol Rep. 2018. PMID: 29611060 Review.
A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors.
Pérez-Pena J, Tibor Fekete J, Páez R, Baliu-Piqué M, García-Saenz JÁ, García-Barberán V, Manzano A, Pérez-Segura P, Esparis-Ogando A, Pandiella A, Gyorffy B, Ocana A. Pérez-Pena J, et al. Among authors: manzano a. Front Immunol. 2019 Dec 18;10:2802. doi: 10.3389/fimmu.2019.02802. eCollection 2019. Front Immunol. 2019. PMID: 31921107 Free PMC article.
A snapshot of COVID-19 infection in patients with solid tumors.
Fuentes-Antrás J, Manzano A, Marquina G, Paz M, Aguado C, Granja M, Benítez J, Ortega J, Priego A, González C, Tejerina-Peces J, Flores P, de Sa AL, Toledano C, Olalla J, de Luna A, Bartolomé J, Pérez-Segura P. Fuentes-Antrás J, et al. Among authors: manzano a. Int J Cancer. 2021 May 15;148(10):2389-2397. doi: 10.1002/ijc.33420. Epub 2020 Dec 19. Int J Cancer. 2021. PMID: 33270902 Free PMC article.
244 results